Wisconsin Alumni Research Foundation

Indiana University

Ben Shen

Gong-Li Tang

Yi-Qiang Cheng

Zhong-Yin Zhang

Michael J Smanski

Hyung-Jin Kwon

Wen Liu

The present invention relates to the cloning and sequence of a biosynthetic gene cluster fromthat produces platensimycin and platencin. Also provided are engineered micro-organisms for the production of these compounds, and analogs thereto, as well as methods of screening for compounds with anti-bacterial activity.

[object Object]

The present invention relates to tautomycetin (TTN) and analogs thereof. Also provided are methods of using TTN and analogs thereof in the treatment of various diseases relating to SHP2 function.

Tautomycetin and tautomycetin analog biosynthesis

The present invention relates to the biosynthetic gene cluster for tautomycetin (TTN) produces tautomycetin. Also provided are engineered micro-organisms for the production of TTN and analogs thereof, as well as methods of screening for compounds for activity.

Genetic and biochemical characterization of the leinamycin biosynthesis gene cluster fromS-140 revealed two PKS genes, lnmI and lnmJ, that encode six PKS modules, none of which contains a cognate AT domain. The AT activity is provided in trans by a discrete protein, LnmG, which loads the malonyl coenzyme A extender unit onto the ACP domains of all six PKS modules. This finding provides a basis for methods of engineering modular polyketide synthases and polyketide synthase/nonribosomal peptide synthetases.

Discrete acyltransferases associated with type I polyketide synthases and methods of use

The present invention provides methods of modifying a biological molecule by C&#x2014;O bond formation utilizing a type II polyketide synthase (PKS) system from the nonactin biosynthesis gene cluster. The type II PKS responsible for biosynthesis of the macrotetralide nonactin includes polypeptides encoded by the nonJK genes. The NonJ and NonK polypeptides have been identified by the inventors as ketoacyl synthases capable of directly catalyzing C&#x2014;O bond formation between substrate molecules. This invention increases the scope and diversity of chemical syntheses available for drug design and combinatorial biosynthesis.

Methods of directing C-O bond formation utilizing a type II polyketide synthase system

The present invention relates to TG-25 and/or analogs thereof and their use of TG-25 in the treatment of cancer. TG-25 inhibits the growth of prostate cells by inhibiting DNA synthesis, more particularly by DNA cleavage.

Oxidative activation and episulfonium ion-mediated DNA alkylation-based anticancer

The present invention provides for fusion proteins that act as targeted drug carries. The proteins are derived from molecules that possess natural drug-binding capabilities that are further engineered to target specific cell types, and optionally to have altered/improved drug binding characteristics. These fusion proteins are useful in, for example, delivery of chemotherapeutic compounds to cancer cells.

Targeted carrier fusions for delivery of chemotherapeutic agents

This invention provides nucleic acid sequences and characterization of the gene cluster responsible for the biosynthesis of the enediyne C-1027 (produced by). Methods are provided for the biosynthesis of enediynes, enediyne analogs and other biological molecules. This invention also provides enediyne and enediyne analogs biosynthesized by manipulation of the C-1027 gene pathway.

Growing community of inventors

Verona, WI, United States of America

Ben Shen